Clinical management of depression and anxiety in HIV-infected adults

AIDS

Volumn 19, Issue 18, 2005, Pages 2057-2067

  Basu, Sanjay ^a   Chwastiak, Lydia A ^a   Bruce, R Douglas ^a  

^a YALE UNIVERSITY   (United States)

Author keywords

Anxiety; Clinical care; Depression; HIV AIDS; Injecting drug users; Substance abuse

Indexed keywords

AMITRIPTYLINE; AMPHETAMINE; ANTIVIRUS AGENT; ANXIOLYTIC AGENT; BENZODIAZEPINE; CITALOPRAM; CLOMIPRAMINE; CYTOCHROME P450 INHIBITOR; DESIPRAMINE; EFAVIRENZ; FLUOXETINE; FLUVOXAMINE; IMIPRAMINE; INDINAVIR; LOPINAVIR; LOPINAVIR PLUS RITONAVIR; MONOAMINE OXIDASE INHIBITOR; NELFINAVIR; NEVIRAPINE; NORADRENALIN UPTAKE INHIBITOR; NORTRIPTYLINE; PAROXETINE; RITONAVIR; SAQUINAVIR; SEROTONIN UPTAKE INHIBITOR; SERTRALINE; TRICYCLIC ANTIDEPRESSANT AGENT; TRIMIPRAMINE; UNINDEXED DRUG; VENLAFAXINE;

ANXIETY DISORDER; BEHAVIOR THERAPY; CHRONIC PAIN; CLINICAL LABORATORY; CLINICAL TRIAL; COGNITIVE THERAPY; COMORBIDITY; DELIRIUM; DIAGNOSTIC AND STATISTICAL MANUAL OF MENTAL DISORDERS; DISEASE ASSOCIATION; DRUG METABOLISM; EXTRAPYRAMIDAL SYMPTOM; FLU LIKE SYNDROME; GENERALIZED ANXIETY DISORDER; HEART ARRHYTHMIA; HIGHLY ACTIVE ANTIRETROVIRAL THERAPY; HUMAN; HUMAN IMMUNODEFICIENCY VIRUS INFECTION; HYPERTENSION; INSOMNIA; LABORATORY TEST; LIVER TOXICITY; MAJOR DEPRESSION; MYOCLONUS; NEUROPATHIC PAIN; OBSESSIVE COMPULSIVE DISORDER; PANIC; POSTTRAUMATIC STRESS DISORDER; PRIORITY JOURNAL; PSYCHIATRIC DIAGNOSIS; PSYCHOTHERAPY; REMISSION; REVIEW; SEIZURE; SEROTONIN SYNDROME; SIDE EFFECT; SOCIAL PHOBIA; SYMPTOMATOLOGY; WITHDRAWAL SYNDROME;

EID: 27944454374     PISSN: 02699370     EISSN: None     Source Type: Journal    
DOI: 10.1097/01.aids.0000182518.84407.32     Document Type: Review

References (106)

1. Bing EG, Burnam MA, Longshore D, Fleishman JA, Sherbourne CD, London AS, et al. Psychiatric disorders and drug use among human immunodeficiency virus-infected adults in the United States. Arch Gen Psychiatry 2001; 58:721-728.
2. Fulk LJ, Kane BE, Phillips KD, Bopp CM, Hand GA. Depression in HIV-infected patients: allopathic, complementary, and alternative treatments. J Psychosom Res 2004; 57:339-351.
3. Maj M, Satz P, Janssen R, Zaudig M, Starace F, D'Elia L, et al. WHO Neuropsychiatric AIDS study, cross-sectional phase II. Neuropsychological and neurological findings. Arch Gen Psychiatry 1994; 51:51-58.
4. Elliott A. Anxiety and HIV infection. STEP Perspect 1998; 98:11-14.
5. Wagner GJ, Kanouse DE, Koegel P, Sullivan G. Adherence to HIV antiretrovirals among persons with serious mental illness. AIDS Patient Care STD 2003; 17:179-186.
6. Himelhoch S, Moore RD, Treisman G, Gebo KA. Does the Presence of a Current Psychiatric Disorder in AIDS Patients Affect the Initiation of Antiretroviral Treatment and Duration of Therapy? J Acquir Immune Defic Syndr 2004; 37:1457-1463.
7. Kemppainen JK, Levine R, Buffum M, Holzemer W, Finley P, Jensen P. Antiretroviral adherence in persons with HIV/AIDS and severe mental illness. J Nerv Ment Dis 2004; 192:395-404.
8. Starace F, Ammassari A, Trotta MP, Murri R, De Longis P, Izzo C, et al. Depression is a risk factor for suboptimal adherence to highly active antiretroviral therapy. J Acquir Immune Defic Syndr 2002; 31 (Suppl 3):136-S139.
9. Cabaj RP. Management of anxiety and depression in HIV-infected patients. J Int Assoc Physicians AIDS Care 1996; 2:11-16.
10. Perdue T, Hagan H, Thiede H, Valleroy L. Depression and HIV risk behavior among Seattle-area injection drug users and young men who have sex with men. AIDS Educ Prevent 2003; 15:81-92.
11. Hutton HE, Lyketsos CG, Zenilman JM, Thompson RE, Erbelding EJ. Depression and HIV risk behaviors among patients in a sexually transmitted disease clinic. Am J Psychiatry 2004; 161:912-914.
12. Douaihy AB, Jou RJ, Gorske T, Salloum IM. Triple diagnosis: dual diagnosis and HIV disease, part 1. AIDS Read 2003; 13:331-332, 339-341.
13. Douaihy AB, Jou RJ, Gorske T, Salloum IM. Triple diagnosis: dual diagnosis and HIV disease, part 2. The AIDS Reader 2003; 13:375-382.
14. Haller DL, Miles DR. Suicidal ideation among psychiatric patients with HIV: psychiatric morbidity and quality of life. AIDS Behav 2003; 7:101-108.
15. Kalichman SC, Heckman T, Kochman A, Sikkema K, Bergholte J. Depression and thoughts of suicide among middle-aged and older persons living with HIV-AIDS. Psychiatric Serv 2000; 51:903-907.
16. Simoni JM, Ng MT. Trauma, coping, and depression among women with HIV/AIDS in New York City. AIDS Care 2000; 12:567-580.
17. Morrison MF, Petitto JM, Ten Have T, Gettes DR, Chiappini MS, Weber AL, et al. Depressive and anxiety disorders in women with HIV infection. Am J Psychiatry 2002; 159:789-796.
18. O'Dowd MA, Biderman DJ, McKegney FP. Incidence of suicidality in AIDS and HIV-positive patients attending a psychiatry outpatient program. Psychosomatics 1993; 34:33-40.
19. McKegney FP, O'Dowd MA. Suicidality and HIV status. Am J Psychiatry 1992; 149:396-398.
20. Asch SM, Kilbourne AM, Gifford AL, Burnam MA, Turner B, Shapiro MF, et al. Underdiagnosis of depression in HIV: who are we missing? J Gen Intern Med 2003; 18:450-460.
21. American Psychiatric Association: Diagnostic and Statistical Manual of Mental Disorders, Fourth Edn, Text Revision. Washington, D.C.: American Psychiatric Association; 2000.
22. Perkins DO, Leserman J, Stern RA, Baum SF, Liao D, Golden RN, et al. Somatic symptoms and HIV infection: relationship to depressive symptoms and indicators of HIV disease. Am J Psychiatry 1995; 152:1776-1781.
23. Fernandez F, Levy JK. Psychopharmacotherapy of psychiatric syndromes in asymptomatic and symptomatic HIV infection. Psychiatric medicine 1991; 9:377-394.
24. American Psychiatric Association. Practice Guideline for the Treatment of Patients with Major Depressive Disorder. Arlington: American Psychiatric Association; 2000.
25. Kalichman SC, Rompa D, Cage M. Distinguishing between overlapping somatic symptoms of depression and HIV disease in people living with HIV-AIDS. J Nerv Mental Dis 2000; 188:662-670.
26. Savard J, Laberge B, Gauthier JG, Ivers H, Bergeron MG. Evaluating anxiety and depression in HIV-infected patients. J Personality Assess 1998; 71:349-367.
27. Kroenke K, Spitzer RL, Williams JB. The PHQ-9: validity of a brief depression severity measure. J Gen Intern Med 2001; 16:606-613.
28. Lowe B, Grafe K, Zipfel S, Witte S, Loerch B, Herzog W. Diagnosing ICD-10 depressive episodes: superior criterion validity of the Patient Health Questionnaire. Psychother Psychosom 2004; 73:386-390.
29. Kroenke K, Spitzer RL, Williams JB. The Patient Health Questionnaire-2: validity of a two-item depression screener. Med Care 2003; 41:1284-1292.
30. Zinkernagel C, Taffe P, Rickenbach M, Amiet R, Ledergerber B, Volkart AC, et al. Importance of mental health assessment in HIV-infected outpatients. J Acquir Immune Defic Syndr: JAIDS 2001; 28:240-249.
31. Edwards N. Differentiating the three D's: delirium, dementia, and depression. Medsurg Nurs 2003; 12:347-357; quiz 358.
32. Thibault JM, Steiner RW. Efficient identification of adults with depression and dementia. Am Fam Physician 2004; 70:1101-1110.
33. Valcour V, Shikuma C, Shiramizu B, Watters M, Poff P, Selnes O, et al. Higher frequency of dementia in older HIV-1 individuals: the Hawaii Aging with HIV-1 Cohort. Neurology 2004; 63:822-827.
34. Price RW. Screening for the AIDS dementia complex. AIDS Read 2002; 12:32-33.
35. Ferrando SJ, Wapenyi K. Psychopharmacological treatment of patients with HIV and AIDS. Psychiat Q 2002; 73:33-49.
36. Sambamoorthi U, Walkup J, Olfson M, Crystal S. Antidepressant treatment and health services utilization among HIV-infected medicaid patients diagnosed with depression. J Gen Intern Med 2000; 15:311-320.
37. Klein DF. SSRIs in children and suicide. Science 2004; 305:1401.
38. Wessely S, Kerwin R. Suicide risk and the SSRIs. JAMA 2004; 292:379-381.
39. Cruess DG, Evans DL, Repetto MJ, Gettes D, Douglas SD, Petitto JM. Prevalence, diagnosis, and pharmacological treatment of mood disorders in HIV disease. Biol Psychiatry 2003; 54:307-316.
40. Angelino AF, Treisman GJ. Management of psychiatric disorders in patients infected with human immunodeficiency virus. Clinical Infect Dis 2001; 33:847-856.
41. Namaka M, Gramlich CR, Ruhlen D, Melanson M, Sutton I, Major J. A treatment algorithm for neuropathic pain. Clin Ther 2004; 26:951-979.
42. Hazell P, O'Connell D, Heathcote D, Henry D. Tricyclic drugs for depression in children and adolescents. Cochrane Database Syst Rev 2002:CD002317.
43. Lee MR, Cohen L, Hadley SW, Goodwin FK. Cognitive-behavioral group therapy with medication for depressed gay men with AIDS or symptomatic HIV infection. Psychiatr Serv 1999; 50:948-952.
44. Lutgendorf SK, Antoni MH, Ironson G, Starr K, Costello N, Zuckerman M, et al. Changes in cognitive coping skills and social support during cognitive behavioral stress management intervention and distress outcomes in symptomatic human immunodeficiency virus (HIV)-seropositive gay men. Psychosom Med 1998; 60:204-214.
45. Kelly JA, Murphy DA, Bahr GR, Kalichman SC, Morgan MG, Stevenson LY, et al. Outcome of cognitive-behavioral and support group brief therapies for depressed. HIV-infected persons. Am J Psychiatry 1993; 150:1679-1686.
46. Markowitz JC, Klerman GL, Clougherty KF, Spielman LA, Jacobsberg LB, Fishman B, et al. Individual psychotherapies for depressed HIV-positive patients. Am J Psychiatry 1995; 152:1504-1509.
47. Ciccolo JT, Jowers EM, Bartholomew JB. The benefits of exercise training for quality of life in HIV/AIDS in the post-HAART era. Sports Med 2004; 34:487-499.
48. Dudgeon WD, Phillips KD, Bopp CM, Hand GA. Physiological and psychological effects of exercise interventions in HIV disease. AIDS Patient Care STDS 2004; 18:81-98.
49. Diego MA, Field T, Hernandez-Reif M, Shaw K, Friedman L, Ironson G. HIV adolescents show improved immune function following massage therapy. Int J Neurosci 2001; 106:35-45.
50. Safren SA, Gershuny BS, Hendriksen E. Symptoms of post-traumatic stress and death anxiety in persons with HIV and medication adherence difficulties. AIDS Patient Care STDs 2003; 17:657-664.
51. Wyatt GE, Myers HF, Loeb TB. Women, trauma, and HIV: an overview. AIDS Behav 2004; 8:401-403.
52. Galvan FH, Collins R, Kanouse DE, Burnam MA, Paddock SM, Beckman R, et al. Abuse in the close relationships of people with HIV. AIDS Behav 2004; 8:441-451.
53. Ballenger JC, Davidson JR, Lecrubier Y, Nutt DJ, Jones RD, Berard RM, et al. Consensus statement on depression, anxiety, and cardiovascular disease. J Clin Psychiatry 2001; 62 (Suppl 8):64-67.
54. Perry S, Fishman B, Jacobsberg L, Frances A. Relationships over 1 year between lymphocyte subsets and psychosocial variables among adults with infection by human immunodeficiency virus.[see comment]. Arch Gen Psychiatry 1992; 49:396-401.
55. Antoni MH. Stress management effects on psychological, endocrinological, and immune functioning in men with HIV infection: empirical support for a psychoneuroimmunological model. Stress 2003; 6:173-188.
56. Charles G, Machowski R, Brohee D, Wilmotte J, Kennes B. Lymphocyte subsets in major depressive patients. Influence of anxiety and corticoadrenal overdrive. Neuropsychobiology 1992; 25:94-98.
57. Atanackovic D, Kroger H, Serke S, Deter HC. Immune parameters in patients with anxiety or depression during psychotherapy. J Affect Disord 2004; 81:201-209.
58. Sakami S, Maeda M, Maruoka T, Nakata A, Komaki G, Kawamura N. Positive coping up- and down-regulates in vitro cytokine productions from T cells dependent on stress levels. Psychother Psychosom 2004; 73:243-251.
59. Andrade L, Eaton WW, Chilcoat HD. Lifetime co-morbidity of panic attacks and major depression in a population-based study: age of onset. Psycholog Med 1996; 26:991-996.
60. Martin S. Some differences between men and women. Monitor Psychol 2001:32.
61. American Psychiatric Association. Practice guideline for the treatment of patients with panic disorder. Work Group on Panic Disorder. Am J Psychiatry 1998; 155:1-34.
62. Spitzer RL, Kroenke K, Linzer M, Hahn SR, Williams JB, deGruy FV., 3rd, et al. Health-related quality of life in primary care patients with mental disorders. Results from the PRIME-MD 1000 Study. JAMA 1995; 274:1511-1517.
63. Schwab JJ, Bialow MR, Clemmons RS, Holzer CE. Hamilton rating scale for depression with medical in-patients. Br J Psychiatry 1967; 113:83-88.
64. Lang AJ, Stein MB. An abbreviated PTSD checklist for use as a screening instrument in primary care. Behav Res Ther 2005; 43:585-594.
65. Shapinsky AC, Rapport LJ, Henderson MJ, Axelrod BN. Civilian PTSD Scales: Relationships With Trait Characteristics and Everyday Distress. Assessment 2005; 12:220-230.
66. Taylor DN. Effects of a behavioral stress-management program on anxiety, mood, self-esteem, and T-cell count in HIV positive men. Psychol Rep 1995; 76:451-456.
67. Antoni MH, Cruess DG, Cruess S, Lutgendorf S, Kumar M, Ironson G, et al. Cognitive-behavioral stress management intervention effects on anxiety, 24-hr urinary norepinephrine output, and T-cytotoxic/suppressor cells over time among symptomatic HIV-infected gay men. J Consult Clin Psychol 2000; 68:31-45.
68. Blanch J, Rousaud A, Hautzinger M, Martinez E, Peri JM, Andres S, et al. Assessment of the efficacy of a cognitive-behavioural group psychotherapy programme for HIV-infected patients referred to a consultation-liaison psychiatry department. Psychother Psychosom 2002; 71:77-84.
69. Ballenger JC. Clinical guidelines for establishing remission in patients with depression and anxiety. J Clin Psychiatry 1999; 60 (Suppl 22):29-34.
70. Mulder CL, Emmelkamp PM, Antoni MH, Mulder JW, Sandfort TG, de Vries MJ. Cognitive-behavioral and experiential group psychotherapy for HIV-infected homosexual men: a comparative study. Psychosomatic medicine 1994; 56:423-431.
71. Tonks A. Treating generalised anxiety disorder. BMJ 2003; 326:700-702.
72. Davidson JR. Use of benzodiazepines in social anxiety disorder, generalized anxiety disorder, and posttraumatic stress disorder. J Clin Psychiatry 2004; 65 (Suppl 5):29-33.
73. Asnis GM, Kohn SR, Henderson M, Brown NL. SSRIs versus non-SSRIs in post-traumatic stress disorder: an update with recommendations. Drugs 2004; 64:383-404.
74. Currier MB, Molina G, Kato M. Citalopram treatment of major depressive disorder in Hispanic HIV and AIDS patients: a prospective study. Psychosomatics 2004; 45:210-216.
75. Darko W, Guharoy R, Rose F, Lehman D, Pappas V. Myoclonus secondary to the concurrent use of trazodone and fluoxetine. Vet Hum Toxicol 2001; 43:214-215.
76. DeSilva KE, Le Flore DB, Marston BJ, Rimland D. Serotonin syndrome in HIV-infected individuals receiving antiretroviral therapy and fluoxetine. AIDS 2001; 15:1281-1285.
77. Judd FK, Mijch AM, Cockram A. Fluoxetine treatment of depressed patients with HIV infection. Austr New Zealand J Psychiatry 1995; 29:433-436.
78. Levine S, Anderson D, Bystritsky A, Baron D. A report of eight HIV-seropositive patients with major depression responding to fluoxetine. J Acquir Immune Defic Syndr 1990; 3:1074-1077.
79. Ouellet D, Hsu A, Qian J, Lamm JE, Cavanaugh JH, Leonard JM, et al. Effect of fluoxetine on pharmacokinetics of ritonavir. Antimicrobial Agents and Chemotherapy 1998; 42:3107-3112.
80. Rabkin JG, Rabkin R, Wagner G. Effects of fluoxetine on mood and immune status in depressed patients with HIV illness. J Clin Psychiatry 1994; 55:92-97.
81. Rabkin JG, Wagner GJ, McElhiney MC, Rabkin R, Lin SH. Testosterone versus fluoxetine for depression and fatigue in HIV/AIDS: a placebo-controlled trial. J Clin Psychopharmacol 2004; 24:379-385.
82. Rabkin JG, Wagner GJ, Rabkin R. Fluoxetine treatment for depression in patients with HIV and AIDS: a randomized, placebo-controlled trial. Am J Psychiatry 1999; 156:101-107.
83. Schwartz JA, McDaniel JS. Double-blind comparison of fluoxetine and desipramine in the treatment of depressed women with advanced HIV disease: a pilot study. Depression Anxiety 1999; 9:70-74.
84. Targ EF, Karasic DH, Diefenbach PN, Anderson DA, Bystritsky A, Fawzy FI. Structured group therapy and fluoxetine to treat depression in HIV-positive persons. Psychosomatics 1994; 35:132-137.
85. Wagner GJ, Maguen S, Rabkin JG. Ethnic differences in response to fluoxetine in a controlled trial with depressed HIV-positive patients. Psychiatric Serv 1998; 49:239-240.
86. Grassi B, Gambini O, Scarone S. Notes on the use of fluvoxamine as treatment of depression in HIV-1-infected subjects. Pharmacopsychiatry 1995; 28:93-94.
87. Elliott AJ, Uldall KK, Bergam K, Russo J, Claypoole K, Roy-Byrne PP. Randomized, placebo-controlled trial of paroxetine versus imipramine in depressed HIV-positive outpatients. Am J Psychiatry 1998; 155:367-372.
88. Grassi B, Gambini O, Garghentini G, Lazzarin A, Scarone S. Efficacy of paroxetine for the treatment of depression in the context of HIV infection. Pharmacopsychiatry 1997; 30:70-71.
89. Ferrando SJ, Goldman JD, Charness WE. Selective serotonin reuptake inhibitor treatment of depression in symptomatic HIV infection and AIDS. Improvements in affective and somatic symptoms. Gen Hosp Psychiatry 1997; 19:89-97.
90. Ferrando SJ, Rabkin JG, de Moore GM, Rabkin R. Antidepressant treatment of depression in HIV-seropositive women. J Clin Psychiatry 1999; 60:741-746.
91. Wagner GJ, Rabkin JG, Rabkin R. A comparative analysis of standard and alternative antidepressants in the treatment of human immunodeficiency virus patients. Comp Psychiatry 1996; 37:402-408.
92. Kieburtz K, Simpson D, Yiannoutsos C, Max MB, Ellis RJ, Marra CM, et al. A randomized trial of amitriptyline and mexiletine for painful neuropathy in HIV infection. AIDS Clinical Trial Group 242 Protocol Team. Neurology 1998; 51:1682-1688.
93. Fernandez F, Levy JK, Samley HR, Pirozzolo FJ, Lachar D, Crowley J, et al. Effects of methylphenidate in HIV-related depression: a comparative trial with desipramine. Int J Psychiatry Med 1995; 25:53-67.
94. von Moltke LL, Greenblatt DJ, Duan SX, Daily JP, Harmatz JS, Shader RI. Inhibition of desipramine hydroxylation (Cytochrome P450-2D6) in vitro by quinidine and by viral protease inhibitors: relation to drug interactions in vivo. J Pharmaceut Sci 1998; 87:1184-1189.
95. Fichtner CG, Braun BG. Bupropion-associated mania in a patient with HIV infection. J Clin Psychopharmacol 1992; 12:366-367.
96. Hesse LM, von Moltke LL, Shader RI, Greenblatt DJ. Ritonavir, efavirenz, and nelfinavir inhibit CYP2B6 activity in vitro: potential drug interactions with bupropion. Drug Metab Dispos. 2001; 29:100-102.
97. Park-Wyllie LY, Antoniou T. Concurrent use of bupropion with CYP2B6 inhibitors, nelfinavir, ritonavir and efavirenz: a case series. AIDS 2003; 17:638-640.
98. Currier MB, Molina G, Kato M. A prospective trial of sustained-release bupropion for depression in HIV-seropositive and AIDS patients. Psychosomatics 2003; 44:120-125.
99. Levin GM, Nelson LA, DeVane CL, Preston SL, Eisele G, Carson SW. A pharmacokinetic drug-drug interaction study of venlafaxine and indinavir. Psychopharmacol Bull 2001; 35:62-71.
100. Elliott AJ, Russo J, Bergam K, Claypoole K, Uldall KK, Roy-Byrne PP. Antidepressant efficacy in HIV-seropositive outpatients with major depressive disorder: an open trial of nefazodone. J Clin Psychiatry 1999; 60:226-231.
101. De Wit S, Cremers L, Hirsch D, Zulian C, Clumeck N, Kormoss N. Efficacy and safety of trazodone versus clorazepate in the treatment of HIV-positive subjects with adjustment disorders: a pilot study. J Int Med Res 1999; 27:223-232.
102. Greenblatt DJ, von Moltke LL, Harmatz JS, Fogelman SM, Chen G, Graf JA, et al. Short-term exposure to low-dose ritonavir impairs clearance and enhances adverse effects of trazodone. J Clin Pharmacol 2003; 43:414-422.
103. Rettman KS, McClintock C. Hepatotoxicity after short-term trazodone therapy. Annals Pharmacother 2001; 35:1559-1561.
104. Elliott AJ, Roy-Byrne PP. Mirtazapine for depression in patients with human immunodeficiency virus. J Clinical Psychopharmacol 2000; 20:265-267.
105. Fernandez F, Levy JK, Galizzi H. Response of HIV-related depression to psychostimulants: case reports. Hosp Commun Psychiatry 1988; 39:628-631.
106. Wagner GJ, Rabkin R. Effects of dextroamphetamine on depression and fatigue in men with HIV: a double-blind, placebo-controlled trial. J Clin Psychiatry 2000; 61:436-440.